For example, STP707 contains two siRNA sequences targeting TGF‐β and COX‐2, and is now under phase I clinical trial (NCT05037149), which is expected to concurrently suppress the expression of TGF‐β and COX‐2 and synergistically inhibit tumor growth.[43] Our work reveals that the reduction‐responsive NPs‐mediated co‐delivery system could highly accumulate in the tumor tissues and significantly enhance the sorafenib sensitivity of HCC tumors via silencing CFL1 expression, thereby leading to a significant inhibition of tumor growth without apparent toxicity. Here, TGFB1 is linked to hepatocellular carcinoma.